Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th.

PRELIMINARY results from the MITO 40 study suggest that Niraparib, a maintenance treatment, may offer significant benefits for patients with no residual disease after primary surgery for ovarian ...

NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (Zentalis ...

This page features the latest news about the Zentalis Pharma share. Zentalis Pharmaceuticals Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is making significant progress in its oncology research, particularly in developing azenosertib, a promising drug for treating platinum-resistant ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such ...

SAN DIEGO—Ingmar Bruns, the Chief Medical (TASE:PMCN) Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common... Vincent Vultaggio, the PAO ...